CA2965498A1 - Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions - Google Patents
Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions Download PDFInfo
- Publication number
- CA2965498A1 CA2965498A1 CA2965498A CA2965498A CA2965498A1 CA 2965498 A1 CA2965498 A1 CA 2965498A1 CA 2965498 A CA2965498 A CA 2965498A CA 2965498 A CA2965498 A CA 2965498A CA 2965498 A1 CA2965498 A1 CA 2965498A1
- Authority
- CA
- Canada
- Prior art keywords
- hpv
- dose
- vaccine
- cancer
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 114
- 201000011510 cancer Diseases 0.000 title claims abstract description 54
- 229960005486 vaccine Drugs 0.000 title claims description 53
- 238000011282 treatment Methods 0.000 title description 30
- 206010040882 skin lesion Diseases 0.000 title description 8
- 231100000444 skin lesion Toxicity 0.000 title description 8
- 239000000203 mixture Substances 0.000 title description 7
- 241001631646 Papillomaviridae Species 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 97
- 230000003902 lesion Effects 0.000 claims abstract description 69
- 108010008038 Synthetic Vaccines Proteins 0.000 claims abstract description 30
- 229940124551 recombinant vaccine Drugs 0.000 claims abstract description 30
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 27
- 206010004146 Basal cell carcinoma Diseases 0.000 claims abstract description 24
- 241000701806 Human papillomavirus Species 0.000 claims description 91
- 229960002566 papillomavirus vaccine Drugs 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 21
- 201000001441 melanoma Diseases 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 201000010153 skin papilloma Diseases 0.000 claims description 12
- 206010059313 Anogenital warts Diseases 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 201000004196 common wart Diseases 0.000 claims description 8
- 229960001438 immunostimulant agent Drugs 0.000 claims description 8
- 239000003022 immunostimulating agent Substances 0.000 claims description 8
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000008380 degradant Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 33
- 201000000849 skin cancer Diseases 0.000 abstract description 28
- 210000004027 cell Anatomy 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- 229940124897 Gardasil Drugs 0.000 description 8
- 229940102767 gardasil 9 Drugs 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 208000000260 Warts Diseases 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
- 201000004201 anogenital venereal wart Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000011256 aggressive treatment Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000001571 immunoadjuvant effect Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 | |
| US62/068,332 | 2014-10-24 | ||
| PCT/US2015/057150 WO2016065281A1 (en) | 2014-10-24 | 2015-10-23 | Cancer and skin lesion treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2965498A1 true CA2965498A1 (en) | 2016-04-28 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2965498A Pending CA2965498A1 (en) | 2014-10-24 | 2015-10-23 | Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (enExample) |
| EP (1) | EP3209676A4 (enExample) |
| JP (1) | JP6663438B2 (enExample) |
| KR (1) | KR102285401B1 (enExample) |
| CN (1) | CN107001430A (enExample) |
| AU (1) | AU2015335652B2 (enExample) |
| BR (1) | BR112017008280A2 (enExample) |
| CA (1) | CA2965498A1 (enExample) |
| CL (1) | CL2017001008A1 (enExample) |
| IL (1) | IL251825B2 (enExample) |
| MX (1) | MX395186B (enExample) |
| MY (1) | MY195018A (enExample) |
| PH (1) | PH12017500754A1 (enExample) |
| SG (1) | SG11201703262UA (enExample) |
| WO (1) | WO2016065281A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017223970B2 (en) * | 2016-02-27 | 2022-01-27 | Hpvvax, Llc | Method and composition for treating cancer or skin lesion using a vaccine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1243655B1 (en) * | 2001-03-23 | 2007-02-21 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modified HPV E6 and E7 genes and proteins useful for vaccination |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| JP5475939B2 (ja) | 2002-12-20 | 2014-04-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｈｐｖ−１６およびｈｐｖ−１８ｌ１ｖｌｐワクチン |
| JP2008502633A (ja) * | 2004-06-16 | 2008-01-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| WO2008112125A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| WO2009127988A1 (en) | 2008-04-16 | 2009-10-22 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| CN102458440A (zh) * | 2009-04-10 | 2012-05-16 | 约翰·霍普金斯大学 | 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp) |
| CN107252489A (zh) * | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| AU2009348078B2 (en) | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
| PE20120563A1 (es) * | 2009-06-25 | 2012-05-17 | Glaxosmithkline Biolog Sa | Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv |
| AR074485A1 (es) | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| JP2014516075A (ja) * | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| CN104203270A (zh) * | 2012-03-18 | 2014-12-10 | 葛兰素史密丝克莱恩生物有限公司 | 针对人乳头状瘤病毒的接种方法 |
| US20150086587A1 (en) * | 2012-03-28 | 2015-03-26 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3054994A4 (en) | 2013-10-13 | 2017-10-11 | The Board of Trustees of the University of Arkansas | Human papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
-
2017
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015335652B2 (en) | 2020-07-02 |
| MX395186B (es) | 2025-03-21 |
| CN107001430A (zh) | 2017-08-01 |
| WO2016065281A1 (en) | 2016-04-28 |
| JP2017531699A (ja) | 2017-10-26 |
| SG11201703262UA (en) | 2017-05-30 |
| CL2017001008A1 (es) | 2017-11-24 |
| IL251825A0 (en) | 2017-06-29 |
| IL251825B1 (en) | 2023-05-01 |
| MX2017005418A (es) | 2017-11-30 |
| AU2015335652A1 (en) | 2017-05-25 |
| BR112017008280A2 (pt) | 2018-01-02 |
| JP6663438B2 (ja) | 2020-03-11 |
| US10238729B2 (en) | 2019-03-26 |
| MY195018A (en) | 2023-01-03 |
| KR102285401B1 (ko) | 2021-08-02 |
| EP3209676A1 (en) | 2017-08-30 |
| IL251825B2 (en) | 2023-09-01 |
| EP3209676A4 (en) | 2018-03-28 |
| PH12017500754A1 (en) | 2017-10-30 |
| US20160114023A1 (en) | 2016-04-28 |
| KR20170072279A (ko) | 2017-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Toh et al. | Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus | |
| Abeck et al. | Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children | |
| Bogani et al. | Human papillomavirus (HPV) vaccination: a call for action in Italy | |
| Tsai | Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine | |
| KR20040030599A (ko) | Ｈｉｖ 항원 및 ｈｓｖ 항원 및/또는 ｈｐｖ 항원을포함하는 다가 백신 | |
| CA3166256A1 (en) | Human papillomavirus (hpv) virus-like particles (vlps) vaccine | |
| Ding et al. | Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer | |
| AU2015335652B2 (en) | Cancer and skin lesion treatment | |
| KR102873848B1 (ko) | 백신을 사용하여 암 또는 피부 병변을 치료하기 위한 방법 및 조성물 | |
| US8101342B2 (en) | DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein | |
| Devadasan et al. | HPV vaccines–A game changer for preventing HPV-related cancers | |
| CN1935262B (zh) | 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 | |
| HK1241898A1 (en) | Cancer and skin lesion treatment | |
| Qiu et al. | Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination | |
| Abdulsalam et al. | Role of HPV vaccines in multiple recalcitrant warts treatment | |
| Ong et al. | Human papillomavirus vaccine for the prevention and treatment of warts: a clinical review | |
| Al-Azmi et al. | Human papillomavirus: manifestations, prevention and treatment: an overview | |
| US10512683B2 (en) | Combination therapies for human papillomavirus-associated diseases comprising administration of therapeutic vaccine and recombinant virus vector | |
| JP2017531699A5 (enExample) | ||
| Mahmoud et al. | Role of Different Immunotherapy Agents in Anogenital Warts Management | |
| Fruscalzo et al. | Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development | |
| Zawadka | Human papilloma virus vaccination | |
| Tezikov et al. | Anogenital Warts: New Opportunities for Prevention | |
| Hussein et al. | The Need for Increased HPV Vaccination Awareness and Access | |
| Elliott | Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201006 |
|
| EEER | Examination request |
Effective date: 20201006 |
|
| EEER | Examination request |
Effective date: 20201006 |
|
| EEER | Examination request |
Effective date: 20201006 |
|
| EEER | Examination request |
Effective date: 20201006 |
|
| EEER | Examination request |
Effective date: 20201006 |
|
| EEER | Examination request |
Effective date: 20201006 |